OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) Files An 8-K Other Events
Item 8.01. Other Events.

On April 12, 2017, OWC Pharmaceutical Research Corp. (the "Registrant") announced the appointment of Alon Sinai, Chief Operating Officer of Registrant’s wholly-owned Israeli subsidiary, One World Cannabis Ltd ("OWC Israel") since July 2014, as the new Interim Chief Executive Officer of OWC Israel, replacing Mr. Ziv Turner.

Alon Sinai, age 49, Chief Operating Officer and Interim Chief Executive Officer of One World Cannabis Ltd, has served as OWC’s liaison with Israel’s major medical institutions and teaching hospital, leading negotiations for the establishment of OWC Israel’s collaboration agreements and clinical trial studies. Mr. Sinai is a retired Lieutenant-Colonel of the IDF who served in its Medical Corps from 1987 to 2013. Mr. Sinai successfully completed the NATO School Oberammergau Program, NATO’s individual training and education facility at the operational level. Mr. Sinai recently served as Head of the Doctrine, Instruction and Training Department of the IDF, where he was responsible for commanding and developing emergency medical facilities, writing professional doctrine and literature for the IDF Medical Corps and working with foreign militaries. Mr. Sinai is currently pursuing his Ph.D. in Health Systems Management at Ben-Gurion University of the Negev, where he previously earned an MA in Health Systems Management and a B.EMS in Emergency Medicine.

Mr. Turner has informed the Registrant that he intends to pursue other business opportunities.

About OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP)

OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.

OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) Recent Trading Information

OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) closed its last trading session up +0.036 at 0.835 with 5,145,728 shares trading hands.